Changes in the apoptotic gene expression profile in CLL patients treated with rituximab combined with cladribine and cyclophosphamide-preliminary results

Ida Franiak-Pietryga, Henryk Maciejewski, Dariusz Wolowiec, Aleksandra Salagacka, Jerzy Z. Blonski, Agnieszka Janus, Aleksandra Kotkowska, Ewa Wawrzyniak, Paolo Ghia, Marek Mirowski, Tadeusz Robak, Anna Korycka-Wolowiec

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The study was aimed to investigate modifications of apoptotic gene expression profile by microarray technique in 10 patients with chronic lymphocytic leukemia by treatment with rituximab, cladribine and cyclophosphamide (RCC) according to IGHV mutational status. The TaqMan ® Low Density Array for 96 gene transcripts was used. Those modifications followed two distinctive patterns largely overlapping the IGHV mutational status. In the IGHV-mutated group, the expression of many proapoptotic genes increased after treatment as compared to initial value. Our results suggest that RCC drugs may act through influence on the expression of some apoptosis-involved genes dependently on the IGVH mutational status.

Original languageEnglish
Pages (from-to)1134-1140
Number of pages7
JournalLeukemia Research
Volume36
Issue number9
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Cladribine
Transcriptome
Cyclophosphamide
Genes
B-Cell Chronic Lymphocytic Leukemia
Apoptosis
Therapeutics
Pharmaceutical Preparations
Rituximab

Keywords

  • Apoptosis
  • Chronic lymphocytic leukemia
  • Gene expression profiling
  • IGHV mutation
  • Microarray

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Franiak-Pietryga, I., Maciejewski, H., Wolowiec, D., Salagacka, A., Blonski, J. Z., Janus, A., ... Korycka-Wolowiec, A. (2012). Changes in the apoptotic gene expression profile in CLL patients treated with rituximab combined with cladribine and cyclophosphamide-preliminary results. Leukemia Research, 36(9), 1134-1140. https://doi.org/10.1016/j.leukres.2012.04.026

Changes in the apoptotic gene expression profile in CLL patients treated with rituximab combined with cladribine and cyclophosphamide-preliminary results. / Franiak-Pietryga, Ida; Maciejewski, Henryk; Wolowiec, Dariusz; Salagacka, Aleksandra; Blonski, Jerzy Z.; Janus, Agnieszka; Kotkowska, Aleksandra; Wawrzyniak, Ewa; Ghia, Paolo; Mirowski, Marek; Robak, Tadeusz; Korycka-Wolowiec, Anna.

In: Leukemia Research, Vol. 36, No. 9, 09.2012, p. 1134-1140.

Research output: Contribution to journalArticle

Franiak-Pietryga, I, Maciejewski, H, Wolowiec, D, Salagacka, A, Blonski, JZ, Janus, A, Kotkowska, A, Wawrzyniak, E, Ghia, P, Mirowski, M, Robak, T & Korycka-Wolowiec, A 2012, 'Changes in the apoptotic gene expression profile in CLL patients treated with rituximab combined with cladribine and cyclophosphamide-preliminary results', Leukemia Research, vol. 36, no. 9, pp. 1134-1140. https://doi.org/10.1016/j.leukres.2012.04.026
Franiak-Pietryga, Ida ; Maciejewski, Henryk ; Wolowiec, Dariusz ; Salagacka, Aleksandra ; Blonski, Jerzy Z. ; Janus, Agnieszka ; Kotkowska, Aleksandra ; Wawrzyniak, Ewa ; Ghia, Paolo ; Mirowski, Marek ; Robak, Tadeusz ; Korycka-Wolowiec, Anna. / Changes in the apoptotic gene expression profile in CLL patients treated with rituximab combined with cladribine and cyclophosphamide-preliminary results. In: Leukemia Research. 2012 ; Vol. 36, No. 9. pp. 1134-1140.
@article{7430f6aedb18478baaafdbcb5e4dfc8d,
title = "Changes in the apoptotic gene expression profile in CLL patients treated with rituximab combined with cladribine and cyclophosphamide-preliminary results",
abstract = "The study was aimed to investigate modifications of apoptotic gene expression profile by microarray technique in 10 patients with chronic lymphocytic leukemia by treatment with rituximab, cladribine and cyclophosphamide (RCC) according to IGHV mutational status. The TaqMan {\circledR} Low Density Array for 96 gene transcripts was used. Those modifications followed two distinctive patterns largely overlapping the IGHV mutational status. In the IGHV-mutated group, the expression of many proapoptotic genes increased after treatment as compared to initial value. Our results suggest that RCC drugs may act through influence on the expression of some apoptosis-involved genes dependently on the IGVH mutational status.",
keywords = "Apoptosis, Chronic lymphocytic leukemia, Gene expression profiling, IGHV mutation, Microarray",
author = "Ida Franiak-Pietryga and Henryk Maciejewski and Dariusz Wolowiec and Aleksandra Salagacka and Blonski, {Jerzy Z.} and Agnieszka Janus and Aleksandra Kotkowska and Ewa Wawrzyniak and Paolo Ghia and Marek Mirowski and Tadeusz Robak and Anna Korycka-Wolowiec",
year = "2012",
month = "9",
doi = "10.1016/j.leukres.2012.04.026",
language = "English",
volume = "36",
pages = "1134--1140",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Ltd",
number = "9",

}

TY - JOUR

T1 - Changes in the apoptotic gene expression profile in CLL patients treated with rituximab combined with cladribine and cyclophosphamide-preliminary results

AU - Franiak-Pietryga, Ida

AU - Maciejewski, Henryk

AU - Wolowiec, Dariusz

AU - Salagacka, Aleksandra

AU - Blonski, Jerzy Z.

AU - Janus, Agnieszka

AU - Kotkowska, Aleksandra

AU - Wawrzyniak, Ewa

AU - Ghia, Paolo

AU - Mirowski, Marek

AU - Robak, Tadeusz

AU - Korycka-Wolowiec, Anna

PY - 2012/9

Y1 - 2012/9

N2 - The study was aimed to investigate modifications of apoptotic gene expression profile by microarray technique in 10 patients with chronic lymphocytic leukemia by treatment with rituximab, cladribine and cyclophosphamide (RCC) according to IGHV mutational status. The TaqMan ® Low Density Array for 96 gene transcripts was used. Those modifications followed two distinctive patterns largely overlapping the IGHV mutational status. In the IGHV-mutated group, the expression of many proapoptotic genes increased after treatment as compared to initial value. Our results suggest that RCC drugs may act through influence on the expression of some apoptosis-involved genes dependently on the IGVH mutational status.

AB - The study was aimed to investigate modifications of apoptotic gene expression profile by microarray technique in 10 patients with chronic lymphocytic leukemia by treatment with rituximab, cladribine and cyclophosphamide (RCC) according to IGHV mutational status. The TaqMan ® Low Density Array for 96 gene transcripts was used. Those modifications followed two distinctive patterns largely overlapping the IGHV mutational status. In the IGHV-mutated group, the expression of many proapoptotic genes increased after treatment as compared to initial value. Our results suggest that RCC drugs may act through influence on the expression of some apoptosis-involved genes dependently on the IGVH mutational status.

KW - Apoptosis

KW - Chronic lymphocytic leukemia

KW - Gene expression profiling

KW - IGHV mutation

KW - Microarray

UR - http://www.scopus.com/inward/record.url?scp=84864026094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864026094&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2012.04.026

DO - 10.1016/j.leukres.2012.04.026

M3 - Article

VL - 36

SP - 1134

EP - 1140

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 9

ER -